1. Human Epididymis Protein 4 (HE4) mRNA as a Prognostic Marker in Ovarian Tumors in Relation to RMI and CA125
   Manar Yehia et al, 2015, International J. of Cancer Research CrossRef
2. The diagnostic value of human epididymis protein 4 as a novel biomarker in patients with renal dysfunction.
   Lunshan Wang et al, 2018, Int Urol Nephrol CrossRef
3. Serum levels of human epididymis protein 4 are more stable than cancer antigen 125 in early and mid-term pregnancy
   Zhiheng Wang et al, 2018, J. Obstet. Gynaecol. Res. CrossRef
4. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay
   Jingjing Yang et al, 2013, Clinical Biochemistry CrossRef
5. Evaluation of serum-based cancer biomarkers: A brief review from a clinical and computational viewpoint
   Sohiya Yotsukura et al, 2015, Critical Reviews in Oncology/Hematology CrossRef
6. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses
   Xinliang Chen et al, 2015, Clinica Chimica Acta CrossRef
7. Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer
   Fatma Beyazit et al, 2015, Arch Gynecol Obstet CrossRef
8. The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer
   L.-T. Jia et al, 2016, Clin Transl Oncol CrossRef
9. Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma
   Dong Mi et al, 2016, J. Obstet. Gynaecol. Res. CrossRef
10. Diagnostic Value of HE4 in Distinguishing Malignant from Benign Pelvic Masses
    Mesut Onal et al, 2016, Indian J Gynecol Oncolog CrossRef
11. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
    Aurélie Pelissier et al, 2016, J Ovarian Res CrossRef
12. Tumor markers of breast cancer: New prospectives
    Ahmed M. Kabel, 2017, Journal of Oncological Sciences CrossRef
13. Serum human epididymis protein 4 levels in colorectal cancer patients
    Yasemi̇n Kemal et al, 2017 CrossRef
14. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review
    Giuseppe Scaletta et al, 2017, Expert Review of Anticancer Therapy CrossRef
15. Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma
    Dong Mi et al, 2020, Arch Gynecol Obstet CrossRef
16. Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction
    Pratistha Koirala et al, 2020, Diagnostics CrossRef
17. Synthetic Naphthoquinone Derivatives as Anticancer Agents in Ovarian Cancer: Cytotoxicity Assay and Investigation of Possible Biological Mechanisms Action
    Renata Dalmaschio Daltoé et al, 2023, Chemistry & Biodiversity CrossRef
18. A label-free dual immunosensor for the simultaneous electrochemical determination of CA125 and HE4 biomarkers for the early diagnosis of ovarian cancer
    Melike Bilgi Kamaç et al, 2023, Anal Bioanal Chem CrossRef
19. Prediction model of adnexal masses with complex ultrasound morphology
    Yuqing Wu et al, 2023, Front. Med. CrossRef
20. Prediction of postoperative residual primary ovarian neoplasm or metastatic lesion close to rectum of serous ovarian carcinoma based on clinical and MR T1-DEI features
    Wenfei Zhang et al, 2024, Acta Radiol CrossRef
21. The predictive value of nomogram for adnexal cystic-solid masses based on O-RADS US, clinical and laboratory indicators
    Chunchun Jin et al, 2024, BMC Med Imaging CrossRef